生技醫藥轉譯創新發展計畫 - 技術支援平台主軸


Program for Translational Innovation of Biopharmaceutical Development-Technology Supporting Platform Axis

訊息公告

2018-11-01

TSPA生技醫藥代表團參訪荷蘭、丹麥和法國

0000-00-00

2018 Bio Taiwan Exhibition 台灣生物科技大展 July 19(Thu)-22(Sun)

2018-06-25

107年度期中進度報告會議

2018-05-25

4th ARO-Japan and TSPA/TCTC-Taiwan Workshop

2017-07-27

TSPA第一次進度報告暨分項五指導委員會

各分項專區


  • 高速藥物篩選與藥物分子庫資源中心

    平台介紹:

    超高速篩選與藥物分子庫資源中心主要任務是搜集獨特之化合物和提供高通量的篩選服務,用以快速尋得具有高生物活性的化合物,分析其分子結構活性與化學資訊,以探索疾病標的分子和瞭解特定功能機制,進而開發治療方法。本團隊作為轉譯醫學新興療法的基礎設施,使用包括200萬個多樣性與獨特性化學小分子庫,以及人類抗體與RNAi/CRISPR非小分子篩選庫,提供客製化的藥物篩選服務。

     

    Introduction:
    The mission of High Throughput Screening and the ChemBank Resource Center is to collect unique molecules and provide HTS services to assist investigators in identifying bioactives for target mechanism study and therapeutics discovery.


  • 候選藥物臨床前毒理ADME服務輔導

    平台介紹:

    提供先導藥品最適化(lead optimization)試驗測試服務,及臨床前毒理試驗服務輔導,支援上游產學研單位之早期藥物研發成果並提供專案管理與提供案源所需之諮詢報告,將先導藥物開發推至臨床前試驗候選藥物階段,協助案源在最短時間內完成法規要求IND-enabling Studies試驗項目,使順利申請IND,取得進行人體臨床試驗之許可。

    Introduction:

    Integrated preclinical support services for Pharma & Biotech companies to facilitate lead identification/optimization, and full fledged GLP IND-enabling DMPK, Safety pharmacology & Toxicology studies to facilitate regulatory submission. Furthermore, provide project management for GLP toxicology studies. This will accelerate the academia-industry transfer of research outputs for further development..

     


  • 藥物化學加值創新研發中心

    平台介紹:

    國衛院生技與藥物研究所歷年來在小分子新藥研發領域積極的建構我國新藥研發能力,從新藥探索研究銜接到新藥臨床前/臨床試驗發展,已發展成為國內重要的創新藥物研發團隊,是國內唯一涵蓋上游至中游新藥研發的政府法人機構。為發揮既有之技術能量與經驗,並配合政府推動「亞太生技醫藥研發產業中心」的政策,生技與藥物研究所積極參與由中研院推動之「生技醫學轉譯創新發展計畫-技術支援平台主軸」,於2017年以整合支援模式設立「藥物化學加值創新研發中心」,提供國家生技研究園區、國內生技廠商及學研界等進行小分子新藥研發所需的藥物化學研究技術平台服務,從「活性化合物至先導化合物最適化」及「先導化合物至候選發展藥物最適化」等之研發工作,透過以客戶需求為導向之藥物化學加值工作,提高候選發展藥物產出之效率與品質,促進廠商轉型投入高附加價值的新穎藥物研發領域,帶動整體生技製藥產業升級。

    Introduction:

    To elaborate the well-established technologies and experiences in innovative drug discovery, and to fit in the vision of government for establishing Taiwan as an Asia-Pacific Biopharmaceutical R&D Industrial Center (亞太生技醫藥研發產業中心), IBPR actively participates in the program organized by the Academia Sinica for Translational Innovation of Biopharmaceutical Development, Technology Supporting Platform Axis Scheme. Under this program, IBPR starts up a new platform called Value-Added MedChem Innovation Center (VMIC) from 2017 to leverage integrated medicinal chemistry research with well-established drug research platform technologies to support the small molecule drug discovery projects for the companies stationed in the National Biotechnology Research Park and academic/research institutes. VMIC’s mission is to provide customer-driven service or collaboration in medicinal chemistry for hit-to-lead and lead-to-candidate. IBPR also exerts its systematic research mechanism and experiences in drug discovery and development stages to bridge the long-existing gap between academia research and industrialization. VMIC’s goal is to enable local pharmaceutical and biotech companies to engage in innovative drug discovery and to upgrade the entirety of the biotechnology and pharmaceutical industry in Taiwan.

     


  • 醣蛋白質藥物開發及生產服務核心

    醣蛋白質藥物開發及生產服務核心


  • 新穎性生物製劑、試劑、高階醫材、治療方法等研發及法規所需之新技術/服務平台

    新穎性生物製劑、試劑、高階醫材、治療方法等研發及法規所需之新技術/服務平台


  • 國際合作組

    本計畫支援四大主題之國際合作:(1)轉譯臨床主軸,(2)中研院政策額度計畫,如臺灣蛋白質計畫和癌症精準醫療計畫,(3)國家生技研究園區,(4)學術國際交流。為營造跨國研究環境與研發合作網絡,激勵國內科研人員積極加入全球尖端科研團隊、參與跨國重要活動,本計畫將提供多元化合作與互訪機制。經由雙邊或多邊協議,與國際合作夥伴國家共同推動各項合作活動,如研究計畫、人員互訪及研討會。亦期增進國際臨床試驗合作的機會,與國際藥廠合作案的建立與投資。
     

    International Collaboration Unit

     

    The International Collaboration Unit supports activities of the four main themes: (1) Translational and Clinical Axis, (2) Key policy-based projects in AS, such as Taiwan Protein Project (TPP) and Cancer Precision Medicine Project, (3) National Biotechnology Research Park, and (4) Other academic exchange.

    The goal of this unit is to promote international collaboration on research projects and clinical trials through exchange visits and the establishment of bilateral/multilateral agreements or partnerships.

     

11529台北市南港區研究院路二段128號